cancer Archives - Halberd Corporation

Dec 5 2022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

By Admin|2022-12-04T16:15:09-05:00December 5th, 2022|Featured, Investor News, Medical, News|0 Comments

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully ...

Nov 17 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

By Admin|2022-11-17T05:15:05-05:00November 17th, 2022|Featured, Investor News, Medical, News|0 Comments

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in ...

Sep 27 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

By Admin|2022-09-26T21:24:04-04:00September 27th, 2022|Featured, Investor News, News, Press Releases|1 Comment

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By Admin|2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing. PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Jul 20 2022

Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary

By Admin|2022-07-19T20:21:05-04:00July 20th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. For now, the new entity will be staffed by Halberd personnel ...

Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By Admin|2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...